ID   BAZ2A_HUMAN             Reviewed;        1905 AA.
AC   Q9UIF9; B3KN66; O00536; O15030; Q68DI8; Q96H26;
DT   30-AUG-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 4.
DT   28-JUN-2023, entry version 209.
DE   RecName: Full=Bromodomain adjacent to zinc finger domain protein 2A;
DE   AltName: Full=Transcription termination factor I-interacting protein 5;
DE            Short=TTF-I-interacting protein 5;
DE            Short=Tip5;
DE   AltName: Full=hWALp3;
GN   Name=BAZ2A; Synonyms=KIAA0314, TIP5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=10662543; DOI=10.1006/geno.1999.6071;
RA   Jones M.H., Hamana N., Nezu J., Shimane M.;
RT   "A novel family of bromodomain genes.";
RL   Genomics 63:40-45(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 7-1905 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [5]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 58-1905 (ISOFORMS 1/2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 359-753.
RC   TISSUE=Lung;
RA   Jansa P., Grummt I.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1065-1905.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1559, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1747; SER-1770 AND SER-1783,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   PHOSPHORYLATION AT SER-1184, AND ACETYLATION AT LYS-680.
RX   PubMed=19578370; DOI=10.1038/ncb1914;
RA   Zhou Y., Schmitz K.M., Mayer C., Yuan X., Akhtar A., Grummt I.;
RT   "Reversible acetylation of the chromatin remodelling complex NoRC is
RT   required for non-coding RNA-dependent silencing.";
RL   Nat. Cell Biol. 11:1010-1016(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1397 AND SER-1783, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-509; SER-1397; SER-1770 AND
RP   SER-1783, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-509; SER-1397; SER-1783 AND
RP   SER-1785, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-509; THR-548; SER-613;
RP   SER-1051; SER-1397 AND SER-1783, ACETYLATION AT LYS-799, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-507, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1150, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25593309; DOI=10.1101/gad.252189.114;
RA   Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W.,
RA   Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.;
RT   "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of
RT   transcription-associated DNA damage that promotes homologous
RT   recombination.";
RL   Genes Dev. 29:197-211(2015).
RN   [21]
RP   INTERACTION WITH BEND3 AND USP21, UBIQUITINATION, AND DEUBIQUITINATION.
RX   PubMed=26100909; DOI=10.1073/pnas.1424705112;
RA   Khan A., Giri S., Wang Y., Chakraborty A., Ghosh A.K., Anantharaman A.,
RA   Aggarwal V., Sathyan K.M., Ha T., Prasanth K.V., Prasanth S.G.;
RT   "BEND3 represses rDNA transcription by stabilizing a NoRC component via
RT   USP21 deubiquitinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:8338-8343(2015).
RN   [22]
RP   FUNCTION, IDENTIFICATION IN THE NORC-1 ISWI CHROMATIN REMODELING COMPLEX,
RP   IDENTIFICATION IN THE NORC-5 CHROMATIN REMODELING COMPLEX, AND INTERACTION
RP   WITH SMARCA1 AND SMARCA5.
RX   PubMed=28801535; DOI=10.15252/embr.201744011;
RA   Oppikofer M., Bai T., Gan Y., Haley B., Liu P., Sandoval W., Ciferri C.,
RA   Cochran A.G.;
RT   "Expansion of the ISWI chromatin remodeler family with new active
RT   complexes.";
RL   EMBO Rep. 18:1697-1706(2017).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-866; LYS-1150; LYS-1172; LYS-1676
RP   AND LYS-1709, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Regulatory subunit of the ATP-dependent NoRC-1 and NoRC-5
CC       ISWI chromatin remodeling complexes, which form ordered nucleosome
CC       arrays on chromatin and facilitate access to DNA during DNA-templated
CC       processes such as DNA replication, transcription, and repair
CC       (PubMed:28801535). Both complexes regulate the spacing of nucleosomes
CC       along the chromatin and have the ability to slide mononucleosomes to
CC       the center of a DNA template (PubMed:28801535). Directly stimulates the
CC       ATPase activity of SMARCA5 in the NoRC-5 ISWI chromatin remodeling
CC       complex (PubMed:28801535). The NoRC-1 ISWI chromatin remodeling complex
CC       has a lower ATP hydrolysis rate than the NoRC-5 ISWI chromatin
CC       remodeling complex (PubMed:28801535). Within the NoRC-5 ISWI chromatin
CC       remodeling complex, mediates silencing of a fraction of rDNA by
CC       recruiting histone-modifying enzymes and DNA methyltransferases,
CC       leading to heterochromatin formation and transcriptional silencing (By
CC       similarity). In the complex, it plays a central role by being recruited
CC       to rDNA and by targeting chromatin modifying enzymes such as HDAC1,
CC       leading to repress RNA polymerase I transcription (By similarity).
CC       Recruited to rDNA via its interaction with TTF1 and its ability to
CC       recognize and bind histone H4 acetylated on 'Lys-16' (H4K16ac), leading
CC       to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac (By
CC       similarity). Specifically binds pRNAs, 150-250 nucleotide RNAs that are
CC       complementary in sequence to the rDNA promoter; pRNA-binding is
CC       required for heterochromatin formation and rDNA silencing (By
CC       similarity). {ECO:0000250|UniProtKB:Q91YE5,
CC       ECO:0000269|PubMed:28801535}.
CC   -!- SUBUNIT: Component of the NoRC-1 ISWI chromatin remodeling complex at
CC       least composed of SMARCA1 and BAZ2A/TIP5, which regulates the spacing
CC       of histone octamers on the DNA template to facilitate access to DNA
CC       (PubMed:28801535). Within the NoRC-1 ISWI chromatin remodeling complex
CC       interacts with SMARCA1; the interaction is direct (PubMed:28801535).
CC       Component of the NoRC-5 ISWI chromatin remodeling complex (also called
CC       the NoRC nucleolar-remodeling complex), at least composed of
CC       SMARCA5/SNF2H and BAZ2A/TIP5, which regulates the spacing of histone
CC       octamers on the DNA template to facilitate access to DNA
CC       (PubMed:28801535). Within the NoRC-5 ISWI chromatin remodeling
CC       complexes interacts with SMARCA5/SNF2H; the interaction is direct
CC       (PubMed:28801535). Interacts with TTF1; the interaction is required for
CC       recruitment of the NoRC-5 ISWI chromatin remodeling complex to rDNA (By
CC       similarity). Interacts with HDAC1 (By similarity). Interacts with SIN3A
CC       (By similarity). Interacts with DNMT1 and DNM3B (By similarity).
CC       Interacts with BEND3 and USP21 (PubMed:26100909).
CC       {ECO:0000250|UniProtKB:Q91YE5, ECO:0000269|PubMed:26100909,
CC       ECO:0000269|PubMed:28801535}.
CC   -!- INTERACTION:
CC       Q9UIF9; P16333: NCK1; NbExp=2; IntAct=EBI-934890, EBI-389883;
CC       Q9UIF9; Q62187: Ttf1; Xeno; NbExp=3; IntAct=EBI-934890, EBI-11705418;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000250|UniProtKB:Q91YE5,
CC       ECO:0000305|PubMed:25593309}. Note=Colocalizes with the basal RNA
CC       polymerase I transcription factor UBF in the nucleolus.
CC       {ECO:0000250|UniProtKB:Q91YE5}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2;
CC         IsoId=Q9UIF9-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q9UIF9-2; Sequence=VSP_037960, VSP_019111;
CC       Name=3;
CC         IsoId=Q9UIF9-3; Sequence=VSP_037961;
CC   -!- TISSUE SPECIFICITY: Expressed at moderate levels in most tissues
CC       analyzed, including heart, brain, placenta, lung, skeletal muscle,
CC       kidney and pancreas.
CC   -!- DOMAIN: The bromo domain and the PHD-type zinc finger recognize and
CC       bind histone H4 acetylated on 'Lys-16' (H4K16ac). These 2 domains play
CC       a central role in the recruitment of chromatin silencing proteins such
CC       as DNMT1, DNMT3B and HDAC1. {ECO:0000250|UniProtKB:Q91YE5}.
CC   -!- DOMAIN: The MBD (methyl-CpG-binding) domain, also named TAM domain,
CC       specifically recognizes and binds a conserved stem-loop structure the
CC       association within pRNA. Binding to pRNA induces a conformational
CC       change of BAZ2A/TIP5 and is essential for targeting the NoRC complex to
CC       the nucleolus. {ECO:0000250|UniProtKB:Q91YE5}.
CC   -!- PTM: Acetylation at Lys-680 by KAT8/MOF promotes its dissociation from
CC       pRNA, affecting heterochromatin formation, nucleosome positioning and
CC       rDNA silencing. Deacetylation by SIRT1 in late S phase enhances pRNA-
CC       binding, allowing de novo DNA methylation and heterochromatin
CC       formation. Acetylation is high during S phase and declines to
CC       background levels in late S phase when the silent copies of rRNA genes
CC       are replicated (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Deubiquitinated by USP21 leading to its
CC       stabilization. {ECO:0000269|PubMed:26100909}.
CC   -!- SIMILARITY: Belongs to the WAL family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB60864.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAG51228.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB032254; BAA89211.1; -; mRNA.
DR   EMBL; CR749379; CAH18232.1; -; mRNA.
DR   EMBL; AC090681; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB002312; BAA20773.2; -; mRNA.
DR   EMBL; AK023830; BAG51228.1; ALT_SEQ; mRNA.
DR   EMBL; AF000422; AAB60864.1; ALT_SEQ; mRNA.
DR   EMBL; BC008965; AAH08965.2; -; mRNA.
DR   CCDS; CCDS44924.1; -. [Q9UIF9-1]
DR   RefSeq; NP_038477.2; NM_013449.3. [Q9UIF9-1]
DR   PDB; 4LZ2; X-ray; 1.76 A; A=1796-1899.
DR   PDB; 4Q6F; X-ray; 1.91 A; A/B/C/D=1673-1728.
DR   PDB; 4QBM; X-ray; 1.65 A; A/B=1796-1899.
DR   PDB; 4QF2; X-ray; 1.70 A; A/B/C/D=1673-1728.
DR   PDB; 5AGQ; NMR; -; A=543-650.
DR   PDB; 5MGJ; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 5MGK; X-ray; 2.30 A; A=1796-1898.
DR   PDB; 5MGL; X-ray; 2.65 A; A=1796-1898.
DR   PDB; 5MGM; X-ray; 2.80 A; A=1796-1898.
DR   PDB; 5OR8; X-ray; 2.40 A; A=1796-1899.
DR   PDB; 5T8R; X-ray; 2.40 A; A/B/C/D=1673-1728.
DR   PDB; 6FAP; X-ray; 2.70 A; A/B/C/D=1673-1728.
DR   PDB; 6FG6; X-ray; 2.40 A; A=1796-1898.
DR   PDB; 6FGF; X-ray; 2.80 A; A=1796-1898.
DR   PDB; 6FGG; X-ray; 1.10 A; A=1796-1899.
DR   PDB; 6FGH; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 6FGI; X-ray; 2.55 A; A=1796-1898.
DR   PDB; 6FGL; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 6FGV; X-ray; 2.50 A; A=1796-1899.
DR   PDB; 6FGW; X-ray; 2.73 A; A=1796-1899.
DR   PDB; 6FHU; X-ray; 2.00 A; A/B/C/D=1673-1728.
DR   PDB; 6FI0; X-ray; 1.90 A; A/B/C/D=1673-1728.
DR   PDB; 6FKP; X-ray; 2.00 A; A/B/C/D=1673-1728.
DR   PDB; 7B7B; X-ray; 1.40 A; A=1796-1898.
DR   PDB; 7B7G; X-ray; 1.43 A; A=1796-1898.
DR   PDB; 7B7I; X-ray; 1.15 A; A=1796-1898.
DR   PDB; 7B82; X-ray; 1.25 A; A=1796-1898.
DR   PDB; 7BC2; X-ray; 2.00 A; A=1796-1898.
DR   PDB; 7BL8; X-ray; 2.50 A; A=1796-1898.
DR   PDB; 7BL9; X-ray; 1.30 A; A=1796-1898.
DR   PDB; 7BLA; X-ray; 1.09 A; A=1796-1898.
DR   PDB; 7BLB; X-ray; 2.30 A; A=1796-1898.
DR   PDB; 7BLC; X-ray; 2.30 A; A=1796-1898.
DR   PDB; 7BLD; X-ray; 2.35 A; A=1796-1898.
DR   PDB; 7FHJ; X-ray; 2.28 A; A/B=536-653.
DR   PDB; 7MWH; X-ray; 2.28 A; A/B=536-653.
DR   PDB; 7MWI; X-ray; 1.80 A; A=536-653.
DR   PDB; 7MWL; X-ray; 1.84 A; A/B=536-653.
DR   PDB; 7QVT; X-ray; 2.60 A; A=1796-1898.
DR   PDB; 7QVU; X-ray; 2.40 A; A=1796-1898.
DR   PDB; 7QVV; X-ray; 2.60 A; A=1796-1898.
DR   PDB; 7QWF; X-ray; 2.25 A; A=1796-1898.
DR   PDB; 7QWU; X-ray; 1.60 A; A=1796-1898.
DR   PDB; 7QWY; X-ray; 2.44 A; A=1796-1898.
DR   PDB; 7QX2; X-ray; 1.43 A; A=1796-1898.
DR   PDB; 7QX9; X-ray; 1.50 A; A=1796-1898.
DR   PDB; 7QXL; X-ray; 1.15 A; A=1796-1898.
DR   PDB; 7QYE; X-ray; 1.65 A; A=1796-1898.
DR   PDB; 7QYO; X-ray; 0.98 A; A=1796-1899.
DR   PDB; 7QYT; X-ray; 2.60 A; A=1796-1898.
DR   PDB; 7QYU; X-ray; 1.50 A; A=1796-1898.
DR   PDB; 7QYV; X-ray; 2.25 A; A=1796-1898.
DR   PDB; 7QYW; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 7QZ0; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 7QZ4; X-ray; 2.30 A; A=1796-1898.
DR   PDB; 7QZB; X-ray; 2.15 A; A=1796-1898.
DR   PDB; 7QZC; X-ray; 2.10 A; A=1796-1898.
DR   PDB; 7QZI; X-ray; 1.98 A; A=1796-1898.
DR   PDB; 7QZT; X-ray; 2.18 A; A=1796-1898.
DR   PDB; 7R01; X-ray; 2.26 A; A=1796-1898.
DR   PDB; 7R0B; X-ray; 2.35 A; A=1796-1898.
DR   PDBsum; 4LZ2; -.
DR   PDBsum; 4Q6F; -.
DR   PDBsum; 4QBM; -.
DR   PDBsum; 4QF2; -.
DR   PDBsum; 5AGQ; -.
DR   PDBsum; 5MGJ; -.
DR   PDBsum; 5MGK; -.
DR   PDBsum; 5MGL; -.
DR   PDBsum; 5MGM; -.
DR   PDBsum; 5OR8; -.
DR   PDBsum; 5T8R; -.
DR   PDBsum; 6FAP; -.
DR   PDBsum; 6FG6; -.
DR   PDBsum; 6FGF; -.
DR   PDBsum; 6FGG; -.
DR   PDBsum; 6FGH; -.
DR   PDBsum; 6FGI; -.
DR   PDBsum; 6FGL; -.
DR   PDBsum; 6FGV; -.
DR   PDBsum; 6FGW; -.
DR   PDBsum; 6FHU; -.
DR   PDBsum; 6FI0; -.
DR   PDBsum; 6FKP; -.
DR   PDBsum; 7B7B; -.
DR   PDBsum; 7B7G; -.
DR   PDBsum; 7B7I; -.
DR   PDBsum; 7B82; -.
DR   PDBsum; 7BC2; -.
DR   PDBsum; 7BL8; -.
DR   PDBsum; 7BL9; -.
DR   PDBsum; 7BLA; -.
DR   PDBsum; 7BLB; -.
DR   PDBsum; 7BLC; -.
DR   PDBsum; 7BLD; -.
DR   PDBsum; 7FHJ; -.
DR   PDBsum; 7MWH; -.
DR   PDBsum; 7MWI; -.
DR   PDBsum; 7MWL; -.
DR   PDBsum; 7QVT; -.
DR   PDBsum; 7QVU; -.
DR   PDBsum; 7QVV; -.
DR   PDBsum; 7QWF; -.
DR   PDBsum; 7QWU; -.
DR   PDBsum; 7QWY; -.
DR   PDBsum; 7QX2; -.
DR   PDBsum; 7QX9; -.
DR   PDBsum; 7QXL; -.
DR   PDBsum; 7QYE; -.
DR   PDBsum; 7QYO; -.
DR   PDBsum; 7QYT; -.
DR   PDBsum; 7QYU; -.
DR   PDBsum; 7QYV; -.
DR   PDBsum; 7QYW; -.
DR   PDBsum; 7QZ0; -.
DR   PDBsum; 7QZ4; -.
DR   PDBsum; 7QZB; -.
DR   PDBsum; 7QZC; -.
DR   PDBsum; 7QZI; -.
DR   PDBsum; 7QZT; -.
DR   PDBsum; 7R01; -.
DR   PDBsum; 7R0B; -.
DR   AlphaFoldDB; Q9UIF9; -.
DR   BMRB; Q9UIF9; -.
DR   SMR; Q9UIF9; -.
DR   BioGRID; 116346; 65.
DR   ComplexPortal; CPX-432; NoRC chromatin remodelling complex.
DR   CORUM; Q9UIF9; -.
DR   IntAct; Q9UIF9; 20.
DR   MINT; Q9UIF9; -.
DR   STRING; 9606.ENSP00000446880; -.
DR   BindingDB; Q9UIF9; -.
DR   ChEMBL; CHEMBL3108642; -.
DR   GuidetoPHARMACOLOGY; 2721; -.
DR   GlyCosmos; Q9UIF9; 1 site, 1 glycan.
DR   GlyGen; Q9UIF9; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q9UIF9; -.
DR   PhosphoSitePlus; Q9UIF9; -.
DR   SwissPalm; Q9UIF9; -.
DR   BioMuta; BAZ2A; -.
DR   DMDM; 257051081; -.
DR   EPD; Q9UIF9; -.
DR   jPOST; Q9UIF9; -.
DR   MassIVE; Q9UIF9; -.
DR   MaxQB; Q9UIF9; -.
DR   PaxDb; Q9UIF9; -.
DR   PeptideAtlas; Q9UIF9; -.
DR   ProteomicsDB; 84511; -. [Q9UIF9-1]
DR   ProteomicsDB; 84512; -. [Q9UIF9-2]
DR   ProteomicsDB; 84513; -. [Q9UIF9-3]
DR   Antibodypedia; 28282; 107 antibodies from 22 providers.
DR   DNASU; 11176; -.
DR   Ensembl; ENST00000551812.5; ENSP00000446880.1; ENSG00000076108.12. [Q9UIF9-1]
DR   GeneID; 11176; -.
DR   KEGG; hsa:11176; -.
DR   UCSC; uc001slq.2; human. [Q9UIF9-1]
DR   AGR; HGNC:962; -.
DR   CTD; 11176; -.
DR   DisGeNET; 11176; -.
DR   GeneCards; BAZ2A; -.
DR   HGNC; HGNC:962; BAZ2A.
DR   HPA; ENSG00000076108; Low tissue specificity.
DR   MIM; 605682; gene.
DR   neXtProt; NX_Q9UIF9; -.
DR   OpenTargets; ENSG00000076108; -.
DR   PharmGKB; PA25272; -.
DR   VEuPathDB; HostDB:ENSG00000076108; -.
DR   eggNOG; KOG1245; Eukaryota.
DR   GeneTree; ENSGT00940000159490; -.
DR   InParanoid; Q9UIF9; -.
DR   OrthoDB; 2912910at2759; -.
DR   PhylomeDB; Q9UIF9; -.
DR   TreeFam; TF329083; -.
DR   PathwayCommons; Q9UIF9; -.
DR   Reactome; R-HSA-427413; NoRC negatively regulates rRNA expression.
DR   SignaLink; Q9UIF9; -.
DR   BioGRID-ORCS; 11176; 41 hits in 1171 CRISPR screens.
DR   ChiTaRS; BAZ2A; human.
DR   GeneWiki; BAZ2A; -.
DR   GenomeRNAi; 11176; -.
DR   Pharos; Q9UIF9; Tchem.
DR   PRO; PR:Q9UIF9; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9UIF9; protein.
DR   Bgee; ENSG00000076108; Expressed in sural nerve and 208 other tissues.
DR   ExpressionAtlas; Q9UIF9; baseline and differential.
DR   Genevisible; Q9UIF9; HS.
DR   GO; GO:0005677; C:chromatin silencing complex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0090536; C:NoRC complex; ISO:ComplexPortal.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0033553; C:rDNA heterochromatin; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016922; F:nuclear receptor binding; NAS:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; ISS:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:UniProtKB.
DR   GO; GO:0006306; P:DNA methylation; ISS:UniProtKB.
DR   GO; GO:0006351; P:DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0031507; P:heterochromatin formation; ISO:ComplexPortal.
DR   GO; GO:0016479; P:negative regulation of transcription by RNA polymerase I; ISO:ComplexPortal.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; ISO:ComplexPortal.
DR   GO; GO:0031062; P:positive regulation of histone methylation; ISO:ComplexPortal.
DR   GO; GO:0000183; P:rDNA heterochromatin formation; ISS:UniProtKB.
DR   GO; GO:0044030; P:regulation of DNA methylation; ISO:ComplexPortal.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0001188; P:RNA polymerase I preinitiation complex assembly; IEA:GOC.
DR   CDD; cd05503; Bromo_BAZ2A_B_like; 1.
DR   CDD; cd01397; HAT_MBD; 1.
DR   CDD; cd15629; PHD_BAZ2A; 1.
DR   Gene3D; 1.20.920.10; Bromodomain-like; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR017956; AT_hook_DNA-bd_motif.
DR   InterPro; IPR037374; BAZ2A/B_Bromo.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR018501; DDT_dom.
DR   InterPro; IPR016177; DNA-bd_dom_sf.
DR   InterPro; IPR001739; Methyl_CpG_DNA-bd.
DR   InterPro; IPR028940; PHD_BAZ2A.
DR   InterPro; IPR028942; WHIM1_dom.
DR   InterPro; IPR028941; WHIM2_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR45915:SF5; BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN PROTEIN 2A; 1.
DR   PANTHER; PTHR45915; TRANSCRIPTION INTERMEDIARY FACTOR; 1.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF02791; DDT; 1.
DR   Pfam; PF01429; MBD; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF15612; WHIM1; 1.
DR   Pfam; PF15613; WSD; 2.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00384; AT_hook; 4.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00571; DDT; 1.
DR   SMART; SM00391; MBD; 1.
DR   SMART; SM00249; PHD; 1.
DR   SUPFAM; SSF47370; Bromodomain; 1.
DR   SUPFAM; SSF54171; DNA-binding domain; 1.
DR   SUPFAM; SSF57903; FYVE/PHD zinc finger; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50827; DDT; 1.
DR   PROSITE; PS50982; MBD; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Bromodomain;
KW   Chromatin regulator; Coiled coil; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Repressor; RNA-binding; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..1905
FT                   /note="Bromodomain adjacent to zinc finger domain protein
FT                   2A"
FT                   /id="PRO_0000211172"
FT   DOMAIN          546..617
FT                   /note="MBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00338"
FT   DOMAIN          848..913
FT                   /note="DDT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00063"
FT   DOMAIN          1810..1880
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DNA_BIND        649..661
FT                   /note="A.T hook 1"
FT   DNA_BIND        670..682
FT                   /note="A.T hook 2"
FT   DNA_BIND        1186..1198
FT                   /note="A.T hook 3"
FT   DNA_BIND        1404..1416
FT                   /note="A.T hook 4"
FT   ZN_FING         1676..1726
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          1..59
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          362..434
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          648..792
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1178..1220
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1283..1318
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1330..1412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1734..1755
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1769..1789
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          693..792
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        28..59
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        653..712
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        736..792
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1347..1377
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         507
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         509
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         548
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         680
FT                   /note="N6-acetyllysine; by KAT8"
FT                   /evidence="ECO:0000269|PubMed:19578370"
FT   MOD_RES         799
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91YE5"
FT   MOD_RES         1051
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91YE5"
FT   MOD_RES         1184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91YE5"
FT   MOD_RES         1397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1559
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         1747
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1770
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1783
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1785
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        866
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1150
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1172
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1709
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         6
FT                   /note="N -> NEAN (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:10662543"
FT                   /id="VSP_037960"
FT   VAR_SEQ         178..207
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:10662543"
FT                   /id="VSP_019111"
FT   VAR_SEQ         1434..1437
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_037961"
FT   VARIANT         498
FT                   /note="V -> E (in dbSNP:rs2230579)"
FT                   /id="VAR_055548"
FT   CONFLICT        106
FT                   /note="N -> S (in Ref. 2; CAH18232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        148
FT                   /note="E -> K (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        155
FT                   /note="Q -> H (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        207
FT                   /note="Q -> P (in Ref. 2; CAH18232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        210
FT                   /note="G -> C (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        236
FT                   /note="G -> C (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        503
FT                   /note="A -> T (in Ref. 2; CAH18232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        601
FT                   /note="V -> L (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        727
FT                   /note="Q -> L (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        747
FT                   /note="Q -> H (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812
FT                   /note="R -> K (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        978
FT                   /note="L -> P (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1032..1033
FT                   /note="EG -> GR (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1190
FT                   /note="G -> S (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1193
FT                   /note="R -> L (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1199
FT                   /note="S -> F (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1205
FT                   /note="L -> F (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1229
FT                   /note="A -> V (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1274
FT                   /note="S -> N (in Ref. 2; CAH18232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1319
FT                   /note="P -> L (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1322
FT                   /note="L -> F (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1340
FT                   /note="P -> L (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1443
FT                   /note="R -> P (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1568
FT                   /note="R -> P (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1598
FT                   /note="E -> K (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1643
FT                   /note="V -> I (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1649
FT                   /note="E -> Q (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1656
FT                   /note="Q -> H (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1663
FT                   /note="Q -> H (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1766
FT                   /note="R -> K (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1781
FT                   /note="G -> R (in Ref. 1; BAA89211)"
FT                   /evidence="ECO:0000305"
FT   HELIX           549..553
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   HELIX           554..557
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   STRAND          561..568
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   STRAND          570..580
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   STRAND          582..584
FT                   /evidence="ECO:0007829|PDB:5AGQ"
FT   HELIX           590..599
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   STRAND          619..627
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   STRAND          630..635
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   TURN            638..640
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   HELIX           641..647
FT                   /evidence="ECO:0007829|PDB:7MWI"
FT   HELIX           1674..1676
FT                   /evidence="ECO:0007829|PDB:4Q6F"
FT   TURN            1680..1682
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   HELIX           1688..1690
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   STRAND          1691..1693
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   STRAND          1695..1698
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   STRAND          1700..1702
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   TURN            1703..1705
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   HELIX           1721..1724
FT                   /evidence="ECO:0007829|PDB:4QF2"
FT   HELIX           1799..1810
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   HELIX           1813..1818
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   TURN            1824..1826
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   HELIX           1830..1833
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   HELIX           1840..1847
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   TURN            1848..1850
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   HELIX           1855..1872
FT                   /evidence="ECO:0007829|PDB:7BLA"
FT   HELIX           1878..1897
FT                   /evidence="ECO:0007829|PDB:7BLA"
SQ   SEQUENCE   1905 AA;  211198 MW;  F364E2AC4BF89EA2 CRC64;
     MEMEANDHFN FTGLPPAPAA SGLKPSPSSG EGLYTNGSPM NFPQQGKSLN GDVNVNGLST
     VSHTTTSGIL NSAPHSSSTS HLHHPSVAYD CLWNYSQYPS ANPGSNLKDP PLLSQFSGGQ
     YPLNGILGGS RQPSSPSHNT NLRAGSQEFW ANGTQSPMGL NFDSQELYDS FPDQNFEVMP
     NGPPSFFTSP QTSPMLGSSI QTFAPSQEVG SGIHPDEAAE KEMTSVVAEN GTGLVGSLEL
     EEEQPELKMC GYNGSVPSVE SLHQEVSVLV PDPTVSCLDD PSHLPDQLED TPILSEDSLE
     PFNSLAPEPV SGGLYGIDDT ELMGAEDKLP LEDSPVISAL DCPSLNNATA FSLLADDSQT
     STSIFASPTS PPVLGESVLQ DNSFDLNNGS DAEQEEMETQ SSDFPPSLTQ PAPDQSSTIQ
     LHPATSPAVS PTTSPAVSLV VSPAASPEIS PEVCPAASTV VSPAVFSVVS PASSAVLPAV
     SLEVPLTASV TSPKASPVTS PAAAFPTASP ANKDVSSFLE TTADVEEITG EGLTASGSGD
     VMRRRIATPE EVRLPLQHGW RREVRIKKGS HRWQGETWYY GPCGKRMKQF PEVIKYLSRN
     VVHSVRREHF SFSPRMPVGD FFEERDTPEG LQWVQLSAEE IPSRIQAITG KRGRPRNTEK
     AKTKEVPKVK RGRGRPPKVK ITELLNKTDN RPLKKLEAQE TLNEEDKAKI AKSKKKMRQK
     VQRGECQTTI QGQARNKRKQ ETKSLKQKEA KKKSKAEKEK GKTKQEKLKE KVKREKKEKV
     KMKEKEEVTK AKPACKADKT LATQRRLEER QRQQMILEEM KKPTEDMCLT DHQPLPDFSR
     VPGLTLPSGA FSDCLTIVEF LHSFGKVLGF DPAKDVPSLG VLQEGLLCQG DSLGEVQDLL
     VRLLKAALHD PGFPSYCQSL KILGEKVSEI PLTRDNVSEI LRCFLMAYGV EPALCDRLRT
     QPFQAQPPQQ KAAVLAFLVH ELNGSTLIIN EIDKTLESMS SYRKNKWIVE GRLRRLKTVL
     AKRTGRSEVE MEGPEECLGR RRSSRIMEET SGMEEEEEEE SIAAVPGRRG RRDGEVDATA
     SSIPELERQI EKLSKRQLFF RKKLLHSSQM LRAVSLGQDR YRRRYWVLPY LAGIFVEGTE
     GNLVPEEVIK KETDSLKVAA HASLNPALFS MKMELAGSNT TASSPARARG RPRKTKPGSM
     QPRHLKSPVR GQDSEQPQAQ LQPEAQLHAP AQPQPQLQLQ LQSHKGFLEQ EGSPLSLGQS
     QHDLSQSAFL SWLSQTQSHS SLLSSSVLTP DSSPGKLDPA PSQPPEEPEP DEAESSPDPQ
     ALWFNISAQM PCNAAPTPPP AVSEDQPTPS PQQLASSKPM NRPSAANPCS PVQFSSTPLA
     GLAPKRRAGD PGEMPQSPTG LGQPKRRGRP PSKFFKQMEQ RYLTQLTAQP VPPEMCSGWW
     WIRDPEMLDA MLKALHPRGI REKALHKHLN KHRDFLQEVC LRPSADPIFE PRQLPAFQEG
     IMSWSPKEKT YETDLAVLQW VEELEQRVIM SDLQIRGWTC PSPDSTREDL AYCEHLSDSQ
     EDITWRGRGR EGLAPQRKTT NPLDLAVMRL AALEQNVERR YLREPLWPTH EVVLEKALLS
     TPNGAPEGTT TEISYEITPR IRVWRQTLER CRSAAQVCLC LGQLERSIAW EKSVNKVTCL
     VCRKGDNDEF LLLCDGCDRG CHIYCHRPKM EAVPEGDWFC TVCLAQQVEG EFTQKPGFPK
     RGQKRKSGYS LNFSEGDGRR RRVLLRGRES PAAGPRYSEE GLSPSKRRRL SMRNHHSDLT
     FCEIILMEME SHDAAWPFLE PVNPRLVSGY RRIIKNPMDF STMRERLLRG GYTSSEEFAA
     DALLVFDNCQ TFNEDDSEVG KAGHIMRRFF ESRWEEFYQG KQANL
//
